Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapeutics entities : Tg therapeutics, inc. save search
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Published: 2024-04-18 (Crawled : 12:00) - globenewswire.com
TGTX | $14.1 2.32% 2.41% 2.3M
|
Health Technology
|
| O: -0.43%
H: 4.57%
C: 0.0%
briumvi neurology sclerosis for meeting therapeutics
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
TGTX | $14.1 2.32% 2.41% 2.3M
|
Health Technology
|
| O: -0.43%
H: 4.57%
C: 0.0%
cd20 briumvi contract sclerosis for therapeutics
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
TGTX | $14.1 2.32% 2.41% 2.3M
|
Health Technology
|
| O: -3.94%
H: 3.0%
C: -0.57%
briumvi neurology presentation sclerosis for meeting therapeutics
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Published: 2024-03-08 (Crawled : 12:30) - globenewswire.com
TGTX | $14.1 2.32% 2.41% 2.3M
|
Health Technology
|
| O: 1.17%
H: 0.44%
C: -7.85%
briumvi sclerosis meeting therapeutics
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Published: 2024-03-01 (Crawled : 12:30) - globenewswire.com
TGTX | $14.1 2.32% 2.41% 2.3M
|
Health Technology
|
| O: 1.86%
H: 4.79%
C: 2.39%
briumvi presentation sclerosis treatment research therapeutics
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
Published: 2024-02-28 (Crawled : 12:00) - globenewswire.com
TGTX | $14.1 2.32% 2.41% 2.3M
|
Health Technology
|
| O: 16.32%
H: 16.75%
C: 8.96%
business update therapeutics financial results
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)Newly issued patents extend exclusivity of ublituximab through 2042
Published: 2024-02-27 (Crawled : 14:30) - biospace.com/
TGTX | $14.1 2.32% 2.41% 2.3M
|
Health Technology
|
| O: 3.44%
H: 1.77%
C: 0.65%
briumvi therapeutics
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)
Published: 2024-02-27 (Crawled : 12:30) - globenewswire.com
TGTX | $14.1 2.32% 2.41% 2.3M
|
Health Technology
|
| O: 3.44%
H: 1.77%
C: 0.65%
briumvi therapeutics
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)
Published: 2024-02-26 (Crawled : 12:00) - globenewswire.com
TGTX | $14.1 2.32% 2.41% 2.3M
|
Health Technology
|
| O: 1.35%
H: 1.67%
C: -1.04%
briumvi therapeutics
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
Published: 2024-02-23 (Crawled : 12:30) - globenewswire.com
TGTX | $14.1 2.32% 2.41% 2.3M
|
Health Technology
|
| O: -0.6%
H: 1.5%
C: -0.3%
conference business update therapeutics financial results
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Published: 2024-02-20 (Crawled : 12:30) - globenewswire.com
TGTX | $14.1 2.32% 2.41% 2.3M
|
Health Technology
|
| O: -0.58%
H: 0.76%
C: -3.78%
briumvi sclerosis treatment research therapeutics
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
Published: 2024-02-12 (Crawled : 13:30) - biospace.com/
TGTX | $14.1 2.32% 2.41% 2.3M
|
Health Technology
|
| O: 1.15%
H: 1.88%
C: 1.81%
DTIL | $9.68 -0.62% 1.12% 8
|
Health Technology
|
| O: 1.56%
H: 3.51%
C: -3.82%
precision million payment treatment therapeutics
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
Published: 2024-01-10 (Crawled : 12:00) - globenewswire.com
TGTX | $14.1 2.32% 2.41% 2.3M
|
Health Technology
|
| O: 7.33%
H: 0.53%
C: -21.2%
year revenue therapeutics
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
Published: 2024-01-09 (Crawled : 13:30) - biospace.com/
TGTX | $14.1 2.32% 2.41% 2.3M
|
Health Technology
|
| O: -8.22%
H: 9.05%
C: 7.47%
DTIL | $9.68 -0.62% 1.12% 8
|
Health Technology
|
| O: 10.0%
H: 14.23%
C: 0.09%
license cell treatment deal therapeutics therapy
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
Published: 2024-01-09 (Crawled : 12:00) - globenewswire.com
TGTX | $14.1 2.32% 2.41% 2.3M
|
Health Technology
|
| O: -8.22%
H: 9.05%
C: 7.47%
DTIL | $9.68 -0.62% 1.12% 8
|
Health Technology
|
| O: 10.0%
H: 14.23%
C: 0.09%
cd19 license cell treatment global commercialization program therapeutics agreement therapy
TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare ConferencePresentation scheduled for Tuesday, January 9, 2024, at 4:30 PM PT
Published: 2024-01-05 (Crawled : 13:30) - biospace.com/
TGTX | $14.1 2.32% 2.41% 2.3M
|
Health Technology
|
| O: -2.5%
H: 12.69%
C: 11.84%
therapeutics
TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-05 (Crawled : 12:30) - globenewswire.com
TGTX | $14.1 2.32% 2.41% 2.3M
|
Health Technology
|
| O: -2.5%
H: 12.69%
C: 11.84%
conference therapeutics
TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceFireside chat scheduled for Wednesday, November 29, 2023, at 2:10 PM ET
Published: 2023-11-27 (Crawled : 14:00) - biospace.com/
TGTX | $14.1 2.32% 2.41% 2.3M
|
Health Technology
|
| O: -1.06%
H: 1.52%
C: 0.2%
therapeutics
TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
Published: 2023-11-27 (Crawled : 12:30) - globenewswire.com
TGTX | $14.1 2.32% 2.41% 2.3M
|
Health Technology
|
| O: -1.06%
H: 1.52%
C: 0.2%
conference therapeutics
TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference
Published: 2023-11-03 (Crawled : 12:00) - globenewswire.com
TGTX | $14.1 2.32% 2.41% 2.3M
|
Health Technology
|
| O: 4.42%
H: 6.35%
C: 1.75%
conference immunology therapeutics
Gainers vs Losers
| 72% | 28% |
Top 10 Gainers
AGBA | $2.5 100.0% 58.33% 200M
|
Finance
EDBL | News | $6.26 66.49% 48.56% 270K
|
MLEC | $2.47 76.43% 38.05% 460K
|
n/a
PEGY | $0.0458 -10.2% 28.77% 79M
|
Manufacturing
PALI | $4.93 4.67% 25.83% 2.1M
|
Manufacturing
SILO | $1.99 0.71% 20.64% 1.8M
|
Finance and Insurance
NNVC | $1.12 1.82% 19.64% 2.5K
|
Health Technology
CANG | $1.34 -4.29% 14.93% 120K
|
Technology Services
AZTR 4 | $0.195 13.85% 42K
|
n/a
TOVX | News | $0.411 -1.01% 12.9% 230K
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.